# SFA Therapeutics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/sfa-therapeutics

- Industry: Biotechnology
- Headquarters: Jenkintown, US
- Website: www.sfatherapeutics.com
- Total disclosed funding: $4M
- Latest round: Seed (Jun 20, 2022)
- Investors on record: 8

## About

SFA Therapeutics, Inc. is a biotechnology firm focused on developing innovative biosynthetic therapies for treating various health challenges, including autoimmune diseases and cancers, through advanced targeted approaches.Founded in 2016 and headquartered in Jenkintown, US, SFA Therapeutics specializes in biosynthetic compound development. In November 2023, the company raised USD 4.00 mn in Seed funding, bringing total funding to USD 4.00 mn. The funding round included participation from investors such as Acequia Capital and Ben Franklin Technology Partners. The founder's history is not detailed in available information.SFA Therapeutics specializes in developing innovative biosynthetic compounds aimed at treating a variety of health challenges, including autoimmune diseases, cancers, infectious diseases, and liver diseases. Their core product offerings leverage a unique platform technology that focuses on the selective targeting of disease-specific pathways, allowing for the creation of drugs that mimic naturally occurring substances within the human body. These biosynthetic molecules, designed to enhance immune function and modulate inflammatory responses, are particularly relevant for conditions such as psoriasis, rheumatoid arthritis, hepatocellular carcinoma, and post-viral inflammatory complications. The company’s products are being developed for diverse therapeutic applications and are primarily targeted at healthcare providers and clinical researchers across North America and Europe, aiming to improve patient outcomes in chronic inflammatory diseases and cancer treatment.SFA Therapeutics operates a revenue model that includes direct partnerships with healthcare institutions and pharmaceutical companies for the development and commercialization of its biosynthetic therapies. The company engages in B2B transactions, focusing on collaborations that allow for the integration of their products into clinical treatment protocols. Revenue generation is anticipated through licensing agreements and the provision of specialized formulations for clinical trials, with a focus on flagship products like SFA-002, which is currently undergoing clinical trials for psoriasis treatment. The company is positioned to capitalize on the growing demand for targeted therapies in autoimmune and chronic inflammatory diseases, establishing itself as a vital player in the biotechnology sector.In November 2023, SFA Therapeutics raised USD 4.00 mn in Seed funding, which will be utilized to advance its lead program, SFA-002, through the ongoing Phase 1b clinical trial in psoriasis and to plan for Phase 2 clinical trial development. The company is looking to expand its market presence by targeting specific regions in North America and Europe for broader distribution of its biosynthetic therapies. Upcoming product launches and further clinical trials are expected to enhance its therapeutic offerings.

## Funding rounds

- Seed, Jun 20, 2022, $4M — Ben Franklin Technology Partners, Acequia Capital, Boost VC, Asymmetry Ventures, Reinforced Ventures, INP Capital, North South Ventures, Savantus Ventures

## Investors

- Ben Franklin Technology Partners (https://capitalatlas.ai/funds/ben-franklin-technology-partners) — Seed
- Acequia Capital (https://capitalatlas.ai/funds/acequia-capital) — Seed
- Boost VC (https://capitalatlas.ai/funds/boost-vc) — Seed
- Asymmetry Ventures (https://capitalatlas.ai/funds/asymmetry-ventures) — Seed
- Reinforced Ventures (https://capitalatlas.ai/funds/reinforced-ventures) — Seed
- INP Capital (https://capitalatlas.ai/funds/inp-capital) — Seed
- North South Ventures (https://capitalatlas.ai/funds/north-south-ventures) — Seed
- Savantus Ventures (https://capitalatlas.ai/funds/savantus-ventures) — Seed